Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:PTIE
- CUSIP: 69562K10
- Web: www.paintrials.com
Capitalization:- Market Cap: $26.69 million
- Outstanding Shares: 6,591,000
Average Prices:- 50 Day Moving Avg: $3.53
- 200 Day Moving Avg: $1.41
- 52 Week Range: $3.39 - $21.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.31
- P/E Growth: 0.04
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.54 per share
- Price / Book: 1.59
Profitability:- EBIDTA: ($11,830,000.00)
- Return on Equity: -60.01%
- Return on Assets: -55.97%
Debt:- Current Ratio: 19.76%
- Quick Ratio: 19.76%
Misc:- Average Volume: 1.02 million shs.
- Beta: 2.33
- Short Ratio: 5.82
Frequently Asked Questions for Pain Therapeutics (NASDAQ:PTIE)
What is Pain Therapeutics' stock symbol?
Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."
When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?
Pain Therapeutics's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.
How were Pain Therapeutics' earnings last quarter?
Pain Therapeutics (NASDAQ:PTIE) released its quarterly earnings data on Tuesday, April, 25th. The company reported ($0.42) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.42). View Pain Therapeutics' Earnings History.
When will Pain Therapeutics make its next earnings announcement?
Where is Pain Therapeutics' stock going? Where will Pain Therapeutics' stock price be in 2017?
1 brokers have issued 12-month price targets for Pain Therapeutics' shares. Their forecasts range from $17.50 to $17.50. On average, they expect Pain Therapeutics' stock price to reach $17.50 in the next year. View Analyst Ratings for Pain Therapeutics.
Who are some of Pain Therapeutics' key competitors?
Some companies that are related to Pain Therapeutics include Midatech Pharma PLC (MTPH), Aeglea BioTherapeutics (AGLE), Inotek Pharmaceuticals Corporation (ITEK), KemPharm (KMPH), Bellerophon Therapeutics (BLPH), ANGLE plc (AGL), ADMA Biologics (ADMA), vTv Therapeutics (VTVT), Orexigen Therapeutics (OREX), Urogen Pharma (URGN), ContraVir Pharmaceuticals (CTRV), Dimension Therapeutics (DMTX), TRACON Pharmaceuticals (TCON), Nivalis Therapeutics (NVLS), Ampio Pharmaceuticals (AMPE), Biopharmx Corp (BPMX), Biopharmx Corp (BPMX) and Biopharmx Corp (BPMX).
Who are Pain Therapeutics' key executives?
Pain Therapeutics' management team includes the folowing people:
- Remi Barbier, Chairman of the Board, President, Chief Executive Officer
- Nadav Friedmann, Chief Medical and Operating Officer, Director
- Michael Marsman Pharm.D., Senior Vice President - Regulatory Affairs
- Robert Z. Gussin Ph.D., Independent Director
- Michael J. O' Donnell Esq., Independent Director
- Saira Ramasastry, Independent Director
- Sanford R. Robertson, Independent Director
- Patrick J. Scannon M.D., Ph.D., Independent Director
Who owns Pain Therapeutics stock?
Pain Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include First Eagle Investment Management LLC (14.43%), Vanguard Group Inc. (3.50%), Renaissance Technologies LLC (1.39%), Geode Capital Management LLC (0.44%), Gabelli Funds LLC (0.38%) and Bank of New York Mellon Corp (0.38%). View Institutional Ownership Trends for Pain Therapeutics.
Who sold Pain Therapeutics stock? Who is selling Pain Therapeutics stock?
Who bought Pain Therapeutics stock? Who is buying Pain Therapeutics stock?
How do I buy Pain Therapeutics stock?
Shares of Pain Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pain Therapeutics' stock price today?
One share of Pain Therapeutics stock can currently be purchased for approximately $4.05.
MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Pain Therapeutics (NASDAQ:PTIE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | $17.50 (332.10% upside) |
Analysts' Ratings History for Pain Therapeutics (NASDAQ:PTIE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/13/2016 | Gabelli | Downgrade | Buy -> Hold | $17.50 | N/A |  |
(Data available from 6/27/2015 forward)
Earnings History for Pain Therapeutics (NASDAQ:PTIE)Earnings History by Quarter for Pain Therapeutics (NASDAQ PTIE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/17/2017 | | | | | | | | |
| 4/25/2017 | Q1 2017 | ($0.42) | ($0.42) | | | View | N/A | |
| 10/20/2016 | Q316 | ($0.63) | ($0.56) | | | View | N/A | |
| 7/19/2016 | Q216 | ($0.98) | ($0.49) | | | View | N/A | |
| 5/5/2016 | Q1 | ($0.70) | ($0.91) | | | View | N/A | |
| 10/30/2014 | Q314 | | ($0.56) | $89.70 million | | View | N/A | |
| 8/5/2014 | Q214 | | ($0.49) | | | View | N/A | |
| 5/6/2014 | Q1 14 | ($0.42) | ($0.56) | $1.96 million | | View | N/A | |
| 2/4/2014 | Q413 | ($0.07) | $5.04 | $2.00 million | $35.24 million | View | N/A | |
| 10/31/2013 | Q313 | ($0.07) | ($0.14) | $2.00 million | $1.96 million | View | N/A | |
| 4/24/2013 | Q1 2013 | ($0.07) | ($0.07) | $2.80 million | $1.96 million | View | N/A | |
| 2/6/2013 | Q4 2012 | ($0.14) | ($0.56) | $2.79 million | $2.47 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Pain Therapeutics (NASDAQ:PTIE)Current Year EPS Consensus Estimate: $1.29 EPS
Next Year EPS Consensus Estimate: $-3.09 EPS
Dividend History by Quarter for Pain Therapeutics (NASDAQ PTIE)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 12/11/2012 | special | $5.25 | | 12/13/2012 | 12/17/2012 | 12/24/2012 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Pain Therapeutics (NASDAQ:PTIE)Insider Ownership Percentage: 32.70%
Insider Trades by Quarter for Pain Therapeutics (NASDAQ:PTIE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/6/2013 | Sanford Robertson | Director | Buy | 50,000 | $3.73 | $186,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Pain Therapeutics (NASDAQ:PTIE)
Latest Headlines for Pain Therapeutics (NASDAQ:PTIE)
| Source: |
|
| Date | Headline |
|---|
 | Breakfast Technical Briefing on Biotech Stocks -- Opko Health, Pain Therapeutics, Trevena, and Dynavax Technologies - PR Newswire (press release)
www.prnewswire.com - June 21 at 2:29 AM |
 | NIH Awards $1.7 Million Research Grant to Pain Therapeutics to Study Alzheimer's Disease - GlobeNewswire (press release)
globenewswire.com - June 7 at 1:13 AM |
 | NIH Awards $1.7 Million Research Grant to Pain Therapeutics to Study Alzheimer’s Disease
finance.yahoo.com - June 5 at 8:00 PM |
 | Pain Therapeutics, Inc. (PTIE) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 3 at 2:02 PM |
| Pain Therapeutics Announces Research Publication on Alzheimer's Disease - GlobeNewswire (press release)
www.globenewswire.com - June 1 at 8:33 PM |
| Pain Therapeutics Announces Research Publication on Alzheimer’s Disease
finance.yahoo.com - June 1 at 8:33 PM |
 | Antibe Therapeutics Engages Topstone Research and Appoints Dr Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346
www.businesswire.com - May 12 at 8:10 AM |
| Pain Therapeutics Announces Reverse Stock Split - GlobeNewswire (press release)
globenewswire.com - May 10 at 11:24 AM |
 | Pain Therapeutics (PTIE) 7-for-1 Reverse Stock Split Effective 05/09 - StreetInsider.com
www.streetinsider.com - May 10 at 11:24 AM |
| Pain Therapeutics Announces Reverse Stock Split
finance.yahoo.com - May 8 at 11:55 AM |
| Pain Therapeutics (PTIE) Receives Daily News Impact Score of 0.17
www.americanbankingnews.com - May 4 at 9:24 PM |
| Pain Therapeutics (PTIE) Getting Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 29 at 6:10 PM |
| Pain Therapeutics, Inc. (PTIE) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 28 at 10:17 AM |
| Positive News Coverage Very Likely to Affect Pain Therapeutics (PTIE) Stock Price
www.americanbankingnews.com - April 26 at 9:40 PM |
| Pain Therapeutics, Inc. (PTIE) Releases Earnings Results, Meets Expectations
www.americanbankingnews.com - April 26 at 4:16 PM |
| Pain Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - April 25 at 6:29 PM |
| Pain Therapeutics reports 1Q loss
finance.yahoo.com - April 25 at 6:29 PM |
| Somewhat Favorable News Coverage Extremely Likely to Affect Pain Therapeutics (PTIE) Stock Price
www.americanbankingnews.com - April 23 at 9:55 AM |
| Pain Therapeutics (PTIE) Earning Somewhat Critical News Coverage, Report Shows
www.americanbankingnews.com - April 18 at 7:59 PM |
| Pain Therapeutics (PTIE) Getting Somewhat Negative News Coverage, Report Shows
www.americanbankingnews.com - April 15 at 2:13 PM |
| Short Interest in Pain Therapeutics, Inc. (PTIE) Grows By 122.3%
www.americanbankingnews.com - April 15 at 7:04 AM |
| Pain Therapeutics, Inc. Forecasted to Earn FY2017 Earnings of ($0.40) Per Share (PTIE)
www.americanbankingnews.com - March 27 at 9:39 AM |
| Gabelli Comments on Pain Therapeutics, Inc.'s FY2021 Earnings (PTIE)
www.americanbankingnews.com - March 24 at 2:28 PM |
| Pain Therapeutics (PTIE) Surges Following Positive REMOXY Regulatory Guidance
www.streetinsider.com - March 21 at 7:09 PM |
 | PTIE Surges After-hours, Valeant Gets FDA Date, JAZZ Hits Right Notes
www.nasdaq.com - March 21 at 10:46 AM |
 | Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE, EGLT)
www.investopedia.com - March 21 at 10:46 AM |
| PAIN THERAPEUTICS INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 21 at 10:46 AM |
 | Pain Therapeutics sets path for resubmitting NDA for pain med REMOXY ER; shares up 65% premarket
seekingalpha.com - March 21 at 7:43 AM |
 | Pain Therapeutics Announces Positive Regulatory Guidance for REMOXY™ ER
feeds.benzinga.com - March 20 at 7:54 PM |
| PAIN THERAPEUTICS INC Financials
finance.yahoo.com - March 11 at 7:10 PM |
| PAIN THERAPEUTICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 7 at 7:15 PM |
| Pain Therapeutics finance chief bids adieu
seekingalpha.com - February 18 at 6:29 PM |
 | Pain Therapeutics Reports 2016 Financial Results
us.rd.yahoo.com - February 18 at 6:29 PM |
| PAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
us.rd.yahoo.com - February 18 at 6:29 PM |
| 9:09 am Pain Therapeutics discloses that it and the FDA reached an agreement on a roadmap to resubmit the New Drug Application for REMOXY ER
us.rd.yahoo.com - February 18 at 6:29 PM |
| Pain Therapeutics Reports 2016 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 17 at 8:05 PM |
| Pain Therapeutics net loss improves in Q4
seekingalpha.com - February 17 at 10:01 AM |
 | Pain Therapeutics PTIE
www.fool.com - January 29 at 12:31 AM |
| Pain Therapeutics to Discuss REMOXY® ER with FDA - GlobeNewswire (press release)
globenewswire.com - December 20 at 1:59 PM |
Pain Therapeutics (PTIE) Chart for Tuesday, June, 27, 2017
